Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?

<table class="fixed-width table-group" id="tab7"><tr><td><table class="table"><colgroup><col style="width:9.88em"/><col style="width:8.66em"/><col style="width:9.12em"/></colgroup><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Therapeutic modality</td><td class="align_center">3-year OS rate (%)</td><td class="align_center">3-year DSS rate (%)</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">NLT</td><td class="align_center">34</td><td class="align_center">46,0</td></tr><tr><td class="align_left">CRT</td><td class="align_center">37</td><td class="align_center">49,0</td></tr><tr><td class="align_left">IMRT</td><td class="align_center">72,0</td><td class="align_center">82,0</td></tr><tr><td class="align_left">RP</td><td class="align_center">73,0</td><td class="align_center">79,0</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>OS: overall survival; DSS: disease-specific survival; NLT: no local treatment; CRT: conformal radiation therapy; IMRT: intensity-modulated radiotherapy; RP: radical prostatectomy.<br/></div></td></tr></table>

<div>Overall survival and disease-specific survival by therapeutic modality, adapted from Satkunasivam et al. (2015) [<a href="/journals/pc/2018/2654572/#B22" target="_blank">15</a>].</div>

Prostate Cancer

tab7

Table 7

Table 7: Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far? 